Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients with previously untreated, locally advanced head and neck squamous cell carcinoma (HNSCC), according to Phase III clinical trial results presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25–30.
This article was originally published on MedicalXpress.com
Fostering a rewarding and fulfilling relationship is no easy task. You and your partner are only human, and, as the saying goes, you are going to make mistakes. However, learning the common relationship mistakes and […]
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
© 2025 SimplyWell.ca